The use of BRAF and MEK inhibitors in stratified patients has led to significant successes in the targeted therapy of melanoma, but the development of resistance is creating a major challenge (Salama and Flaherty, 2013; Wellbrock, 2014). Here, MAP2K7 is linked to melanoma.